Clinical Trials Logo

Clinical Trial Summary

The hypothesis of this study is that a gastroesophageal reflux recommended treatment with proton pump inhibitor (dose and duration) compared to placebo significantly reduces both the signs and symptoms of laryngopharyngeal reflux and comorbid chronic rhinosinusitis. Primary objective was to determine whether 8 weeks of treatment with omeprazole 20 mg ones daily (OD) significantly reduces the signs and symptoms of laryngopharyngeal reflux when compared to placebo in patients with laryngopharyngeal reflux with comorbid chronic rhinosinusitis. Secondary objectives were to determine whether 8 weeks of treatment with omeprazole 20 mg OD significantly reduces the signs and symptoms of comorbid chronic rhinosinusitis in patients with laryngopharyngeal reflux when compared to matching placebo; and to investigate the association of the severity of signs and symptoms of laryngopharyngeal reflux with the ones of chronic rhinosinusitis in the same group of patients. The research was carried out as a double blind randomized placebo controlled trial. Patients were randomized into two groups in an approximate 1:1 ratio using a concealed random sequence. After randomization and initial assessment treatment was initialized. Patients on active treatment were given omeprazole 20 mg once daily half an hour before breakfast for 8 weeks, while those in the placebo group were given matching placebo tablets using the same regimen for 8 weeks as the group on the active treatment. Patients were reassessed at the end of treatment for signs and symptoms of laryngopharyngeal reflux and comorbid chronic rhinosinusitis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03086070
Study type Interventional
Source Children's Hospital Srebrnjak
Contact
Status Completed
Phase Phase 4
Start date January 1, 2010
Completion date June 30, 2010

See also
  Status Clinical Trial Phase
Recruiting NCT05895929 - The Role of IL5 in Epithelial Cell Integrity Early Phase 1
Completed NCT03673956 - Topical Antibiotics in Chronic Rhinosinusitis Phase 1/Phase 2
Recruiting NCT03970655 - Functional Endoscopic Sinus Surgery Study Phase 1/Phase 2
Not yet recruiting NCT04514120 - Alsaleh-Javer Endoscopic Sinus Score (AJESS) System N/A
Recruiting NCT03963648 - NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP N/A
Recruiting NCT05009758 - Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps N/A
Active, not recruiting NCT05553951 - Adherence in Global Airways N/A
Completed NCT03563521 - Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
Completed NCT05035654 - LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study) Phase 2
Withdrawn NCT03369574 - Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab
Recruiting NCT05400616 - Nasal Microbiota Transfer Therapy in Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) N/A
Recruiting NCT04628442 - Tissue Immune Interaction in Nasal Polyposis
Completed NCT04041609 - LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study) Phase 2
Completed NCT04048070 - The Effect of Enhanced Recovery After Surgery in Endoscopic Sinus Surgery N/A
Recruiting NCT03439865 - Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis Early Phase 1
Recruiting NCT05857228 - Viral and Epigenetic Influences in CRSwNP
Completed NCT03122795 - Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) N/A
Recruiting NCT05295459 - Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2) Phase 3
Completed NCT04858802 - A Clinical Evaluation of PROPEL® Contour Sinus Implant N/A
Completed NCT04572516 - Botulium Toxin Type A In Non Infectious Chronic Rhinosinusitis Phase 3